advertisement
Abstract #125412 Published in IGR 25-2
Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation
Vera V; Sheybani A; Panarelli JF; Grover DS; Lee J; Craven ER; Samuelson TW; Ahmed IIKClinical Ophthalmology 2025; 19: 325-347
The XEN®45 Glaucoma Treatment System (gel stent; Allergan, an AbbVie company, Irvine, CA, USA) is a minimally invasive bleb-forming surgical device that was originally approved to lower intraocular pressure by diverting the aqueous humor from the anterior chamber to the subconjunctival space (like trabeculectomy) following ab-interno placement. Since approval of the gel stent in multiple countries, the implantation technique has evolved considerably, being performed ab interno or ab externo with open or closed conjunctiva, based on patients' needs and/or surgeons' preferences. Additional technical variations that can facilitate gel stent placement and/or improve outcomes have also emerged. This article aims to increase awareness of these developments to facilitate informed decision-making and improve surgical success and outcomes for patients.
Allergan, an AbbVie company, Irvine, CA, USA.
Full article